Francos, Aquitanos y Vascones. Testimonios arqueológicos al Sur de los Pirineos

This article is a brief advance of the archaeological investigations that the author is making about the Late Antiquity age on the Western Pyrenees. The finding in Alava and Navarre of two necropolis of the Vlth and Vllth centuries, with a worth mentioning number of weapons and with funerary rituals and offerings that re fer not to a H ispanic-Wisigothic cultural context but to a north Pyrennean one ( of the Aquitainne area to be exact), allows to open a discussion to restate the actual historiographic interpretations for this period.Este artículo constituye un breve avance de las investigaciones que, desde hace algunos años, viene efectuando el autor sobre la época tardoantigua en el área de los Pirineos más occidentales. El descubrimiento en tierras alavesas y navarras de dos necrópolis de los siglos VI y VII, con un número de armas digno de mención y con rituales, depósitos y ajuares funerarios que nos remiten no a un contexto cultural hispanovisigodo sino al norte de los Pirineos, permite abrir un debate que replantee las interpretaciones historiográficas actuales para este período

Second-line treatment in advanced gastric cancer : Data from the Spanish AGAMENON registry

Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. The study population comprised patients with AGC in the AGAMENON registry who had received second-line. The objective was to describe the pattern of second-line therapies administered, progression-free survival following second-line (PFS-2), and post-progression survival since first-line (PPS). 2311 cases with 2066 progression events since first-line (89.3%) were recorded; 245 (10.6%) patients died during first-line treatment and 1326/2066 (64.1%) received a second-line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9-3.3) and 5.8 months (5.5-6.3), respectively. The most widely used strategies were monoCT (56.9%), polyCT (15.0%), ramucirumab+CT (12.6%), platinum-reintroduction (8.3%), trastuzumab+CT (6.1%), and ramucirumab (1.1%). PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Correlation between PFS since first-line and OS was moderate in the series as a whole (Kendall's τ = 0.613), lower in those subjects who received second-line (Kendall's τ = 0.539), especially with ramucirumab+CT (Kendall's τ = 0.413). This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines

Documentación y análisis arquitectónico en el País Vasco. Algunas experiencias llevadas a cabo en Álava-España

This article, which describes the work carried out in the Basque Country, seeks to be a -necessarily brief- reflection of a dynamics generated two years ago (1993) around the Historical Heritage Service of the Architecture and Building Office of the Diputación Foral de Álava in collaboration with Archaeology Department of the Basque Country University.<br><br>Este artículo, que describe el trabajo desarrollado en el País Vasco, quiere ser reflejo -forzosamente breve- de una dinámica generada hace dos años (1993) en torno al Servicio de Patrimonio Histórico de la Dirección de Arquitectura y Urbanismo de la Diputación Foral de Álava, en colaboración con el Área de Arqueología de la Universidad del País Vasco

Forest maturity has a stronger influence on the prevalence of spider monkeys than howler monkeys in an anthropogenically impacted rainforest landscape.

Funder: Bournemouth UniversityThe transformation and depletion of primary forest over the past few decades have placed almost half of the world's primate species under the threat of extinction. Developing any successful conservation program for primates requires distribution and demography data, as well as an understanding of the relationships between these factors and their habitat. Between March and June 2010 and 2011 we collected data on the presence and demographic parameters of howler and spider monkeys by carrying out surveys, and validated our findings using local knowledge. We then examined the relationship between forest type and the presence of these primates at 54 sites in the northern area of the Selva Zoque Corridor, Mexico. We detected 86 spider monkey groups across 31 plots and censused 391 individuals (mean ± SD = 5.9 ± 3.0 individuals per sub-group, n = 67 sub-groups). We also detected 69 howler monkey groups across 30 plots and censused 117 individuals (mean ± SD = 5.3 ± 2.4 individuals per group, n = 22 groups). Howler monkey presence was not related to any specific vegetation type, while spider monkeys were present in areas with a higher percentage of tall forest (trees > 25 m high). Overall, spider monkeys were more prevalent than howler monkeys in our sampling sites and showed demographic characteristics similar to those in better protected areas, suggesting that the landscape features in the Uxpanapa Valley are suitable for their needs. Conversely, howler monkey presence was found to be more limited than in other regions, possibly due to the extended presence of spider monkeys

External validity of docetaxel triplet trials in advanced gastric cancer : are there patients who still benefit?

Background: The purpose of our study was to develop an online calculator to estimate the effect of docetaxel triplets (DPF) in first line of advanced gastric cancer (AGC), and to assess the external validity of docetaxel trials in individual patients. Methods: The study includes patients with HER2(-) AGC treated with platin and fluoropyrimidine (PF) or with DPF in first line. Treatment effect and interactions were assessed using Bayesian accelerated failure time models. Result: The series comprises 1376 patients; 238 treated with DPF and 1138 with PF between 2008 and 2019. DPF was associated with increased progression-free survival (PFS) and overall survival (OS) with time ratio (TR) 1.27 (95% credible interval [CrI], 1.15-1.40), and TR 1.19 (95% CrI, 1.09-1.27), respectively. Serious adverse events were more common with DPF, particularly hematological effects (32% vs 22%). Younger participants received greater DPF dose density without achieving greater disease control, while severe toxicity was likewise higher. DPF yielded superior OS in Lauren intestinal (TR 1.27, 95% CrI, 1.08-1.11) vs diffuse subtype (TR 1.17, 95% CrI, 1.09-1.24) and the probability of increasing OS > 15% was 90% vs 67% in each subtype, respectively. The effect dwindles over time, which can be attributed to pathological changes and clinical practice changes. Conclusion: Our study confirms the effect of DPF is highly dependent on several clinical-pathological variables, with discreet and gradually declining benefit over platinum doublets in later years, at the expense of increased toxicity. These results may help to underpin the idea that external validity of AGC trials should be revised regularly

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry

Background: Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. Materials and methods: The study population comprised patients with AGC in the AGAMENON registry who had received second-line. The objective was to describe the pattern of second-line therapies administered, progression-free survival following second-line (PFS-2), and post-progression survival since first-line (PPS). Results: 2311 cases with 2066 progression events since first-line (89.3%) were recorded; 245 (10.6%) patients died during first-line treatment and 1326/2066 (64.1%) received a second-line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9-3.3) and 5.8 months (5.5-6.3), respectively. The most widely used strategies were monoCT (56.9%), polyCT (15.0%), ramucirumab+CT (12.6%), platinum-reintroduction (8.3%), trastuzumab+CT (6.1%), and ramucirumab (1.1%). PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Correlation between PFS since first-line and OS was moderate in the series as a whole (Kendall's τ = 0.613), lower in those subjects who received second-line (Kendall's τ = 0.539), especially with ramucirumab+CT (Kendall's τ = 0.413). Conclusion: This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines